Last Update: Feb 9 @ 2:17 PM
From the July 2, 2007 edition
Life Sciences
EpiVax awarded a grant for hemophilia therapy
By David Ortiz
A Providence-based biotechnology pharmaceutical firm that genetically engineers new vaccines has received a $528,313 grant to begin developing a novel treatment for hemophilia. More »
This item is available in full to subscribers. Please log in to continue.
To purchase a copy of this article for $2.00, click here.
Latest Local Press Releases
View / Post »
From the PR Newswire
View All »

Contents of this site are all Copyright © 2010, Providence Business News. All rights reserved. Powered By: Creative Circle Advertising Solutions, Inc.